Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer

Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer

Cancer immunotherapy is an option to enhance physiological defence mechanism to fight cancer, where natural substances (e.g., antigen/antibody) or small synthetic molecule can be utilized to improve and restore the immune system to stop or slacken the development of malignant cells, stop metastasis...

Full description

Bibliographic Details
Main Authors:	Islam, Mohammad Kaisarul, Stanslas, Johnson
Format:	Article
Published:	Elsevier 2021

Similar Items

The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
by: Yanwen Zhong, et al.
Published: (2019-05-01)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
by: Yan Guo, et al.
Published: (2021-04-01)

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules
by: Marialuigia Fantacuzzi, et al.
Published: (2024-02-01)

Pharmacological modulation of apoptosis and autophagy in pancreatic cancer treatment
by: Stanslas, Johnson, et al.
Published: (2022)

Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets
by: Annoor Awadasseid, et al.
Published: (2024-03-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
by: Edyta Zyla, et al.
Published: (2021-08-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy
by: Dan Liu, et al.
Published: (2023-07-01)

Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
by: Samia S. Messeha, et al.
Published: (2021-05-01)

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
by: Magdalena Bojko, et al.
Published: (2024-04-01)

Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment
by: Binbin Cheng, et al.
Published: (2023-03-01)

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
by: Shengzhe Jin, et al.
Published: (2024-03-01)

New Immunological Markers in Chromoblastomycosis—The Importance of PD-1 and PD-L1 Molecules in Human Infection
by: Italo N. Cavallone, et al.
Published: (2023-12-01)

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells
by: Meng-Yuan Dai, et al.
Published: (2022-11-01)

Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment
by: Li Liu, et al.
Published: (2023-07-01)

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
by: Luís Costa, et al.
Published: (2022-07-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
by: نرگس عبدالهی, et al.
Published: (2023-11-01)

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
by: Adil Parvez, et al.
Published: (2023-12-01)

Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
by: Anaïs Perrichet, et al.
Published: (2020-11-01)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
by: Faisal K. Alkholifi, et al.
Published: (2022-11-01)

Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology
by: Tuan Hiep Tran, et al.
Published: (2022-04-01)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
by: Shun-Long Ou, et al.
Published: (2023-04-01)

Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis
by: Tao Huang, et al.
Published: (2022-12-01)

PD-1/PD-L1 and DNA Damage Response in Cancer
by: Mateusz Kciuk, et al.
Published: (2023-02-01)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
by: Mariacarmela Santarpia, et al.
Published: (2020-06-01)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
by: Giuseppe Luigi Banna, et al.
Published: (2020-07-01)

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
by: Dolores Isla, et al.
Published: (2023-08-01)

Investigation of the PD-1 and PD-L1 Immune Checkpoint Molecules Throughout Healthy Human Pregnancy and in Nonpregnant Women
by: Matyas Meggyes, et al.
Published: (2020-08-01)

The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis
by: Michał Adamczyk, et al.
Published: (2023-06-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)

Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1
by: Nian Liu, et al.
Published: (2023-02-01)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
by: Siqing Jiang, et al.
Published: (2022-09-01)

The PD-1/PD-L1 Axis in the Biology of MASLD
by: Rosaria Maria Pipitone, et al.
Published: (2024-03-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
by: Seri Jeong, et al.
Published: (2021-10-01)

Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation
by: Jianhuai Liang, et al.
Published: (2023-01-01)

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment
by: Simona Serratì, et al.
Published: (2023-08-01)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
by: Trine Vilsbøll Larsen, et al.
Published: (2019-06-01)